中存在的黄类药物的潜在治疗作用,调节血管内皮生长因子信号,调节血管生成
Yipeng Lin1, Janney Z Wang1, Yihe Niu1
1Molecular Drug Development Group, Sydney Pharmacy School, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.
Phytotherapy research : PTR
|August 9, 2025
概括
蜂的黄胺显示出作为抗血管生成剂的潜力. 这些化合物可以通过调节血管内皮生长因子 (VEGF) 信号来抑制病态血管生长,为癌症等疾病提供治疗可能性.
科学领域:
- 自然产品 化学 化学
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 蜂是一种由蜜蜂收集的树脂,含有多种生物活性化合物,特别是黄类.
- 血管新生,新血管的形成,对于发育至关重要,但涉及到癌症和视网膜疾病等疾病.
- 血管内皮生长因子 (VEGF) 是血管生成的关键调节者.
研究的目的:
- 审查黄素作为抗血管生成剂的治疗潜力.
- 探索作用机制,重点关注VEGF信号调制.
- 评估治疗血管新生驱动疾病的潜力.
主要方法:
- 关于 прополис黄和血管生成的临床前和临床研究的文献综述.
- 对中的黄化合物成分的分析.
- 对调查VEGF信号通路的研究进行审查.
主要成果:
- 在临床前模型中,的黄素,包括素和素,显示出抗血管性质.
- 这些黄类药物通过干扰VEGF信号通路来抑制血管生成.
- 有证据表明,对于涉及病理性血管生成的疾病有潜在的治疗应用.
结论:
- 的黄酸是开发抗血管性疗法的有希望的天然来源.
- 需要进一步的体内和临床研究来确认疗效和安全性.
- 调节VEGF信号与的黄类化合物可以为各种疾病提供新的治疗策略.
相关概念视频
Regulation of Angiogenesis and Blood Supply
2.7K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.7K
Mechanism of Angiogenesis
5.8K
Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
5.8K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
254
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
254
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
645
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
645


